Research progress of early optimal metabolic therapy for diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Jia Qiong ¹ ,  Luo Xiangxia ² , Su Meigui ¹ , Hu Tingting ¹ , Zhang Yujie ¹ , Tang Yanhong ³

1. Clinical College of Traditional Chinese Medicine of Gansu University of Traditional Chinese Medicine, Lanzhou 730030, China;
2. Scientific Research Office of Gansu Academy of Traditional Chinese Medicine, Lanzhou 730050, China;
3. Ophthalmology of Linxia Hospital of Traditional Chinese Medicine, Linxia Hui Autonomous Prefecture 731100, China;

Corresponding author：

Luo Xiangxia, Email: jessica_lxx@163.com

Keywords：

Diabetic retinopathy; Review; Optimal metabolic therapy

DOI：

10.3760/cma.j.cn511434-20200304-00096

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Diabetic retinopathy (DR) is one of the main cause of severe visual impairment in diabetic patients. Most of the existing treatments are aimed at patients with intermediate and advanced stages of vision impairment, and are invasive treatments with limited effects. Therefore, it is urgent for non-invasive new therapies and new targets to prevent the risk of DR or delay the progress of DR. Early optimization of metabolic therapies, which are strict control of blood glucose, blood pressure and blood lipid in the early stage of diabetes, may prevent or improve potential and reversible microangiopathy, however, there is still a lack of comprehensive and effective drug targeted therapy and unified clinical application standards. Therefore, this study summarizes the application of new hypoglycemic drugs and some antihypertensive and lipid-lowering drugs in the prevention and treatment of DR in recent years, in order to provide some reference for the clinical early prevention and treatment of this disease.

Citation： Jia Qiong, Luo Xiangxia, Su Meigui, Hu Tingting, Zhang Yujie, Tang Yanhong. Research progress of early optimal metabolic therapy for diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2021, 37(1): 68-72. doi: 10.3760/cma.j.cn511434-20200304-00096 Copy

1.	Zhang J, Wang Y, Li L, et al. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy[J]. Ren Fail, 2018, 40(1): 243-251. DOI: 10.1080/0886022X.2018.1456453.
2.	Song W, Zhu YW. Chinese medicines in diabetic retinopathy therapies[J]. Chin J Integr Med, 2019, 25(4): 316-320. DOI: 10.1007/s11655-017-2911-0.
3.	Al-Kharashi AS. Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy[J]. Saudi J Ophthalmol, 2018, 32(4): 318-323. DOI: 10.1016/j.sjopt.2018.05.002.
4.	Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
5.	Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy[J]. Prog Retin Eye Res, 2016, 51: 156-186. DOI: 10.1016/j.preteyeres.2015.08.001.
6.	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344. DOI: 10.19538/j.nk2018040108.Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(4): 292-344. DOI: 10.19538/j.nk2018040108.
7.	Elkjaer AS, Lynge SK, Grauslund J. Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review[J]. Acta Ophthalmol, 2020, 98(4): 329-336. DOI: 10.1111/aos.14377.
8.	Chen Q, Ma Q, Wu C, et al. Macular vascular fractal dimension in the deep capillary layer as an early indicator of microvascular loss for retinopathy in type 2 diabetic patients[J]. Invest Ophthalmol Vis Sci, 2017, 58(9): 3785-3794. DOI: 10.1167/iovs.17-21461.
9.	Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study[J]. BMJ, 2000, 321(7258): 405-412. DOI: 10.1136/bmj.321.7258.405.
10.	Wang NK, Lai CC, Wang JP, et al. Risk factors associated with the development of retinopathy 10 yr after the diagnosis of juvenile-onset type 1 diabetes in Taiwan: a cohort study from the CGJDES[J]. Pediatric Diabetes, 2016, 17(6): 407-416. DOI: 10.1111/pedi.12312.
11.	Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action[J]. Cell Metab, 2013, 17(6): 819-837. DOI: 10.1016/j.cmet.2013.04.008.
12.	Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody[J]. Endocrinology, 2014, 155(4): 1280-1290. DOI: 10.1210/en.2013-1934.
13.	Tonneijck L, Smits MM, van Raalte DH, et al. Incretin-based drugs and renoprotection-is hyperfiltration key?[J]. Kidney Int, 2015, 87(3): 660-661. DOI: 10.1038/ki.2014.398.
14.	Shin S, Le Lay J, Everett LJ, et al. CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse β-cells[J]. Mol Metab, 2014, 3(8): 803-812. DOI: 10.1016/j.molmet.2014.08.001.
15.	Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies[J]. Ther Adv Endocrinol Metab, 2015, 6(1): 19-28. DOI: 10.1177/2042018814559725.
16.	Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis[J]. J Hepatol, 2016, 64(2): 399-408. DOI: 10.1016/j.jhep.2015.08.038.
17.	Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy[J/OL]. Int J Mol Sci, 2018, 19(4): 942[2018-03-22]. https://pubmed.ncbi.nlm.nih.gov/29565290/. DOI: 10.3390/ijms19040942.
18.	Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American diabetes association[J]. Diabetes Care, 2017, 40(3): 412-418. DOI: 10.2337/dc16-2641.
19.	Hernández C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes[J]. Diabetes, 2016, 65(1): 172-187. DOI: 10.2337/db15-0443.
20.	Sampedro J, Bogdanov P, Ramos H, et al. New insights into the mechanisms of action of topical administration of GLP-1 in an experimental model of diabetic retinopathy[J/OL]. J Clin Med, 2019, 8(3): 339[2015-09-17]. https://pubmed.ncbi.nlm.nih.gov/30862093/. DOI: 10.3390/jcm8030339.
21.	郑宏华, 雷雨, 陈小红, 等. 利拉鲁肽在早期糖尿病视网膜病变中的视网膜神经保护作用[J]. 国际眼科杂志, 2019, 19(2): 275-279. DOI: 10.3980/j.issn.1672-5123.2019.2.21.Zheng HH, Lei Y, Chen XH, et al. Retinal neuroprotective effect of GLP-1 analogs liraglutide in early diabetic retinopathy[J]. Int Eye Sci, 2019, 19(2): 275-279. DOI: 10.3980/j.issn.1672-5123.2019.2.21.
22.	Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes[J]. Diabetologia, 2011, 54(4): 965-978. DOI: 10.1007/s00125-010-2028-x.
23.	Chung YR, Ha KH, Kim HC, et al. Dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-based cohort study[J]. Diabetes Metab J, 2019, 43(5): 640-648. DOI: 10.4093/dmj.2018.0137.
24.	Dietrich N, Kolibabka M, Busch S, et al. The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy[J/OL]. PLoS One, 2016, 11(12): e0167853[2019-02-20]. https://pubmed.ncbi.nlm.nih.gov/27942008/. DOI: 10.1371/journal.pone.0167853.
25.	Gonçalves A, Marques C, Leal E, et al. Dipeptidyl peptidase-Ⅳinhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats[J]. Biochim Biophys Acta, 2014, 1842(9): 1454-1463. DOI: 10.1016/j.bbadis.2014.04.013.
26.	Hernández C, Bogdanov P, Solà-Adell C, et al. Topical administration of DPP-Ⅳ inhibitors prevents retinal neurodegeneration in experimental diabetes[J]. Diabetologia, 2017, 60(11): 2285-2298. DOI: 10.1007/s00125-017-4388-y.
27.	Cheng M, Huang K, Zhou J, et al. A critical role of src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart[J]. J Mol Cell Cardiol, 2015, 81: 49-53. DOI: 10.1016/j.yjmcc.2015.01.024.
28.	Lee CS, Kim YG, Cho HJ, et al. Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation[J/OL]. Sci Rep, 2016, 6: 29393[2016-07-06]. https://pubmed.ncbi.nlm.nih.gov/27381080/. DOI: 10.1038/srep29393.
29.	Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence[J]. Postgrad Med, 2019, 131(4): 251-260. DOI: 10.1080/00325481.2019.1601404.
30.	May M, Framke T, Junker B, et al. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology[J/OL]. Ther Adv Endocrinol Metab, 2019, 10: 2042018819891886[2019-12-11]. https://pubmed.ncbi.nlm.nih.gov/31853361/. DOI: 10.1177/2042018819891886.
31.	Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years[J]. J Diabetes Complications, 2015, 29(8): 1295-1303. DOI: 10.1016/j.jdiacomp.2015.07.011.
32.	Herat LY, Matthews VB, Rakoczy PE, et al. Focusing on sodium glucose cotransporter-2 and the sympathetic nervous system: potential impact in diabetic retinopathy[J/OL]. Int J Endocrinol, 2018, 2018: 9254126[2018-07-05]. https://pubmed.ncbi.nlm.nih.gov/30123269/. DOI: 10.1155/2018/9254126.
33.	Sha W, Wen S, Chen L, et al. The role of SGLT2 inhibitor on the treatment of diabetic retinopathy[J/OL]. J Diabetes Res, 2020, 2020: 8867875[2020-11-12]. https://pubmed.ncbi.nlm.nih.gov/33274239/. DOI: 10.1155/2020/8867875.
34.	Yoshizumi H, Ejima T, Nagao T, et al. Recovery from diabetic macular edema in a diabetic patient after minimal dose of a sodium glucose co-transporter 2 inhibitor[J]. Am J Case Rep, 2018, 19: 462-466. DOI: 10.12659/AJCR.909708.
35.	Kelly MS, Lewis J, Huntsberry AM, et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease[J]. Postgrad Med, 2019, 131: 31-42. DOI: 10.1080/00325481.2019.1549459.
36.	Ott C, Jumar A, Striepe K, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation[J/OL]. Cardiovasc Diabetol, 2017, 16(1): 26[2017-02-23]. https://pubmed.ncbi.nlm.nih.gov/28231831/. DOI: 10.1186/s12933-017-0510-1.
37.	Inzucchi SE, Wanner C, Hehnke U, et al. Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG outcome trial[J/OL]. Diabetes Care, 2019, 42(4): e53-e55[2019-01-31]. https://pubmed.ncbi.nlm.nih.gov/30705060/. DOI: 10.2337/dc18-1355.
38.	Takatsuna Y, Ishibashi R, Tatsumi T, et al. Sodium-glucose cotransporter 2 inhibitors improve chronic diabetic macular edema[J/OL]. Case Rep Ophthalmol Med, 2020, 2020: 8867079[2020-11-12]. https://pubmed.ncbi.nlm.nih.gov/33274092/. DOI: 10.1155/2020/8867079.
39.	UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38[J]. BMJ, 1998, 317(7160): 703-713. DOI: 10.1136/bmj.317.7160.703.
40.	Wang S, Xu L, Jonas JB, et al. Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population: the Beijing Eye Study[J]. Ophthalmology, 2009, 116(12): 2373-2380. DOI: 10.1016/j.ophtha.2009.05.041.
41.	Kanda A, Noda K, Saito W, et al. (Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy[J]. Diabetologia, 2012, 55(11): 3104-3113. DOI: 10.1007/s00125-012-2702-2.
42.	Mahajan N, Arora P, Sandhir R. Perturbed biochemical pathways and associated oxidative stress lead to vascular dysfunctions in diabetic retinopathy[J/OL]. Oxid Med Cell Longev, 2019, 2019: 8458472[2019-03-06]. https://pubmed.ncbi.nlm.nih.gov/30962865/. DOI: 10.1155/2019/8458472.
43.	Prasad T, Roksnoer LC, Zhu P, et al. Beneficial effects of combined AT1 receptor/neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye[J]. Invest Ophthalmol Vis Sci, 2016, 57(15): 6722-6730. DOI: 10.1167/iovs.16-20289.
44.	Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2015, 3(4): 263-274. DOI: 10.1016/S2213-8587(14)70256-6.
45.	Zhang HY, Wang JY, Ying GS, et al. Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients[J]. J Zhejiang Univ Sci B, 2013, 14(5): 392-399. DOI: 10.1631/jzus.B1200237.
46.	Li J, Wang JJ, Chen D, et al. Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes[J]. Exp Eye Res, 2009, 89(1): 71-78. DOI: 10.1016/j.exer.2009.02.013.
47.	Kang EY, Chen TH, Garg SJ, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy[J]. JAMA Ophthalmol, 2019, 137(4): 363-371. DOI: 10.1001/jamaophthalmol.2018.6399.
48.	Gurreri A, Pazzaglia A, Schiavi C. Role of statins and ascorbic acid in the natural history of diabetic retinopathy: a new, affordable therapy?[J]. Ophthalmic Surg Lasers Imaging Retina, 2019, 50(5): S23-S27. DOI: 10.3928/23258160-20190108-06.
49.	Chen N, Jiang K, Yan GG. Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(19): 8630-8636. DOI: 10.26355/eurrev_201910_19180.
50.	Yeh PT, Wang LC, Chang SW, et al. Effect of fenofibrate on the expression of inflammatory mediators in a diabetic rat model[J]. Curr Eye Res, 2019, 44(10): 1121-1132. DOI: 10.1080/02713683.2019.1622020.
51.	Liu Q, Zhang X, Cheng R, et al. Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation[J]. Cell Tissue Res, 2019, 376(2): 165-177. DOI: 10.1007/s00441-018-2974-z.
52.	Qiu F, Meng T, Chen Q, et al. Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration[J]. Mol Pharm, 2019, 16(5): 1958-1970. DOI: 10.1021/acs.molpharmaceut.8b01319.
53.	Mozetic V, Pacheco RL, Latorraca COC, et al. Statins and/or fibrates for diabetic retinopathy: a systematic review and meta-analysis[J/OL]. Diabetol Metab Syndr, 2019, 11: 92[2019-11-08]. https://pubmed.ncbi.nlm.nih.gov/31719846/. DOI: 10.1186/s13098-019-0488-9.

1. Zhang J, Wang Y, Li L, et al. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy[J]. Ren Fail, 2018, 40(1): 243-251. DOI: 10.1080/0886022X.2018.1456453.
2. Song W, Zhu YW. Chinese medicines in diabetic retinopathy therapies[J]. Chin J Integr Med, 2019, 25(4): 316-320. DOI: 10.1007/s11655-017-2911-0.
3. Al-Kharashi AS. Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy[J]. Saudi J Ophthalmol, 2018, 32(4): 318-323. DOI: 10.1016/j.sjopt.2018.05.002.
4. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
5. Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy[J]. Prog Retin Eye Res, 2016, 51: 156-186. DOI: 10.1016/j.preteyeres.2015.08.001.
6. 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344. DOI: 10.19538/j.nk2018040108.Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(4): 292-344. DOI: 10.19538/j.nk2018040108.
7. Elkjaer AS, Lynge SK, Grauslund J. Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review[J]. Acta Ophthalmol, 2020, 98(4): 329-336. DOI: 10.1111/aos.14377.
8. Chen Q, Ma Q, Wu C, et al. Macular vascular fractal dimension in the deep capillary layer as an early indicator of microvascular loss for retinopathy in type 2 diabetic patients[J]. Invest Ophthalmol Vis Sci, 2017, 58(9): 3785-3794. DOI: 10.1167/iovs.17-21461.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study[J]. BMJ, 2000, 321(7258): 405-412. DOI: 10.1136/bmj.321.7258.405.
10. Wang NK, Lai CC, Wang JP, et al. Risk factors associated with the development of retinopathy 10 yr after the diagnosis of juvenile-onset type 1 diabetes in Taiwan: a cohort study from the CGJDES[J]. Pediatric Diabetes, 2016, 17(6): 407-416. DOI: 10.1111/pedi.12312.
11. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action[J]. Cell Metab, 2013, 17(6): 819-837. DOI: 10.1016/j.cmet.2013.04.008.
12. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody[J]. Endocrinology, 2014, 155(4): 1280-1290. DOI: 10.1210/en.2013-1934.
13. Tonneijck L, Smits MM, van Raalte DH, et al. Incretin-based drugs and renoprotection-is hyperfiltration key?[J]. Kidney Int, 2015, 87(3): 660-661. DOI: 10.1038/ki.2014.398.
14. Shin S, Le Lay J, Everett LJ, et al. CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse β-cells[J]. Mol Metab, 2014, 3(8): 803-812. DOI: 10.1016/j.molmet.2014.08.001.
15. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies[J]. Ther Adv Endocrinol Metab, 2015, 6(1): 19-28. DOI: 10.1177/2042018814559725.
16. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis[J]. J Hepatol, 2016, 64(2): 399-408. DOI: 10.1016/j.jhep.2015.08.038.
17. Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy[J/OL]. Int J Mol Sci, 2018, 19(4): 942[2018-03-22]. https://pubmed.ncbi.nlm.nih.gov/29565290/. DOI: 10.3390/ijms19040942.
18. Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American diabetes association[J]. Diabetes Care, 2017, 40(3): 412-418. DOI: 10.2337/dc16-2641.
19. Hernández C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes[J]. Diabetes, 2016, 65(1): 172-187. DOI: 10.2337/db15-0443.
20. Sampedro J, Bogdanov P, Ramos H, et al. New insights into the mechanisms of action of topical administration of GLP-1 in an experimental model of diabetic retinopathy[J/OL]. J Clin Med, 2019, 8(3): 339[2015-09-17]. https://pubmed.ncbi.nlm.nih.gov/30862093/. DOI: 10.3390/jcm8030339.
21. 郑宏华, 雷雨, 陈小红, 等. 利拉鲁肽在早期糖尿病视网膜病变中的视网膜神经保护作用[J]. 国际眼科杂志, 2019, 19(2): 275-279. DOI: 10.3980/j.issn.1672-5123.2019.2.21.Zheng HH, Lei Y, Chen XH, et al. Retinal neuroprotective effect of GLP-1 analogs liraglutide in early diabetic retinopathy[J]. Int Eye Sci, 2019, 19(2): 275-279. DOI: 10.3980/j.issn.1672-5123.2019.2.21.
22. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes[J]. Diabetologia, 2011, 54(4): 965-978. DOI: 10.1007/s00125-010-2028-x.
23. Chung YR, Ha KH, Kim HC, et al. Dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-based cohort study[J]. Diabetes Metab J, 2019, 43(5): 640-648. DOI: 10.4093/dmj.2018.0137.
24. Dietrich N, Kolibabka M, Busch S, et al. The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy[J/OL]. PLoS One, 2016, 11(12): e0167853[2019-02-20]. https://pubmed.ncbi.nlm.nih.gov/27942008/. DOI: 10.1371/journal.pone.0167853.
25. Gonçalves A, Marques C, Leal E, et al. Dipeptidyl peptidase-Ⅳinhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats[J]. Biochim Biophys Acta, 2014, 1842(9): 1454-1463. DOI: 10.1016/j.bbadis.2014.04.013.
26. Hernández C, Bogdanov P, Solà-Adell C, et al. Topical administration of DPP-Ⅳ inhibitors prevents retinal neurodegeneration in experimental diabetes[J]. Diabetologia, 2017, 60(11): 2285-2298. DOI: 10.1007/s00125-017-4388-y.
27. Cheng M, Huang K, Zhou J, et al. A critical role of src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart[J]. J Mol Cell Cardiol, 2015, 81: 49-53. DOI: 10.1016/j.yjmcc.2015.01.024.
28. Lee CS, Kim YG, Cho HJ, et al. Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation[J/OL]. Sci Rep, 2016, 6: 29393[2016-07-06]. https://pubmed.ncbi.nlm.nih.gov/27381080/. DOI: 10.1038/srep29393.
29. Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence[J]. Postgrad Med, 2019, 131(4): 251-260. DOI: 10.1080/00325481.2019.1601404.
30. May M, Framke T, Junker B, et al. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology[J/OL]. Ther Adv Endocrinol Metab, 2019, 10: 2042018819891886[2019-12-11]. https://pubmed.ncbi.nlm.nih.gov/31853361/. DOI: 10.1177/2042018819891886.
31. Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years[J]. J Diabetes Complications, 2015, 29(8): 1295-1303. DOI: 10.1016/j.jdiacomp.2015.07.011.
32. Herat LY, Matthews VB, Rakoczy PE, et al. Focusing on sodium glucose cotransporter-2 and the sympathetic nervous system: potential impact in diabetic retinopathy[J/OL]. Int J Endocrinol, 2018, 2018: 9254126[2018-07-05]. https://pubmed.ncbi.nlm.nih.gov/30123269/. DOI: 10.1155/2018/9254126.
33. Sha W, Wen S, Chen L, et al. The role of SGLT2 inhibitor on the treatment of diabetic retinopathy[J/OL]. J Diabetes Res, 2020, 2020: 8867875[2020-11-12]. https://pubmed.ncbi.nlm.nih.gov/33274239/. DOI: 10.1155/2020/8867875.
34. Yoshizumi H, Ejima T, Nagao T, et al. Recovery from diabetic macular edema in a diabetic patient after minimal dose of a sodium glucose co-transporter 2 inhibitor[J]. Am J Case Rep, 2018, 19: 462-466. DOI: 10.12659/AJCR.909708.
35. Kelly MS, Lewis J, Huntsberry AM, et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease[J]. Postgrad Med, 2019, 131: 31-42. DOI: 10.1080/00325481.2019.1549459.
36. Ott C, Jumar A, Striepe K, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation[J/OL]. Cardiovasc Diabetol, 2017, 16(1): 26[2017-02-23]. https://pubmed.ncbi.nlm.nih.gov/28231831/. DOI: 10.1186/s12933-017-0510-1.
37. Inzucchi SE, Wanner C, Hehnke U, et al. Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG outcome trial[J/OL]. Diabetes Care, 2019, 42(4): e53-e55[2019-01-31]. https://pubmed.ncbi.nlm.nih.gov/30705060/. DOI: 10.2337/dc18-1355.
38. Takatsuna Y, Ishibashi R, Tatsumi T, et al. Sodium-glucose cotransporter 2 inhibitors improve chronic diabetic macular edema[J/OL]. Case Rep Ophthalmol Med, 2020, 2020: 8867079[2020-11-12]. https://pubmed.ncbi.nlm.nih.gov/33274092/. DOI: 10.1155/2020/8867079.
39. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38[J]. BMJ, 1998, 317(7160): 703-713. DOI: 10.1136/bmj.317.7160.703.
40. Wang S, Xu L, Jonas JB, et al. Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population: the Beijing Eye Study[J]. Ophthalmology, 2009, 116(12): 2373-2380. DOI: 10.1016/j.ophtha.2009.05.041.
41. Kanda A, Noda K, Saito W, et al. (Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy[J]. Diabetologia, 2012, 55(11): 3104-3113. DOI: 10.1007/s00125-012-2702-2.
42. Mahajan N, Arora P, Sandhir R. Perturbed biochemical pathways and associated oxidative stress lead to vascular dysfunctions in diabetic retinopathy[J/OL]. Oxid Med Cell Longev, 2019, 2019: 8458472[2019-03-06]. https://pubmed.ncbi.nlm.nih.gov/30962865/. DOI: 10.1155/2019/8458472.
43. Prasad T, Roksnoer LC, Zhu P, et al. Beneficial effects of combined AT1 receptor/neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye[J]. Invest Ophthalmol Vis Sci, 2016, 57(15): 6722-6730. DOI: 10.1167/iovs.16-20289.
44. Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2015, 3(4): 263-274. DOI: 10.1016/S2213-8587(14)70256-6.
45. Zhang HY, Wang JY, Ying GS, et al. Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients[J]. J Zhejiang Univ Sci B, 2013, 14(5): 392-399. DOI: 10.1631/jzus.B1200237.
46. Li J, Wang JJ, Chen D, et al. Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes[J]. Exp Eye Res, 2009, 89(1): 71-78. DOI: 10.1016/j.exer.2009.02.013.
47. Kang EY, Chen TH, Garg SJ, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy[J]. JAMA Ophthalmol, 2019, 137(4): 363-371. DOI: 10.1001/jamaophthalmol.2018.6399.
48. Gurreri A, Pazzaglia A, Schiavi C. Role of statins and ascorbic acid in the natural history of diabetic retinopathy: a new, affordable therapy?[J]. Ophthalmic Surg Lasers Imaging Retina, 2019, 50(5): S23-S27. DOI: 10.3928/23258160-20190108-06.
49. Chen N, Jiang K, Yan GG. Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(19): 8630-8636. DOI: 10.26355/eurrev_201910_19180.
50. Yeh PT, Wang LC, Chang SW, et al. Effect of fenofibrate on the expression of inflammatory mediators in a diabetic rat model[J]. Curr Eye Res, 2019, 44(10): 1121-1132. DOI: 10.1080/02713683.2019.1622020.
51. Liu Q, Zhang X, Cheng R, et al. Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation[J]. Cell Tissue Res, 2019, 376(2): 165-177. DOI: 10.1007/s00441-018-2974-z.
52. Qiu F, Meng T, Chen Q, et al. Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration[J]. Mol Pharm, 2019, 16(5): 1958-1970. DOI: 10.1021/acs.molpharmaceut.8b01319.
53. Mozetic V, Pacheco RL, Latorraca COC, et al. Statins and/or fibrates for diabetic retinopathy: a systematic review and meta-analysis[J/OL]. Diabetol Metab Syndr, 2019, 11: 92[2019-11-08]. https://pubmed.ncbi.nlm.nih.gov/31719846/. DOI: 10.1186/s13098-019-0488-9.

Previous Article
Progress in diagnosis and treatment of diabetic retinopathy with leukemia
Next Article
Research advances in the mechanism of subthreshold micropulse laser in diabetic macular edema

Chinese Journal of Ocular Fundus Diseases

Research progress of early optimal metabolic therapy for diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content